Prasugrel: A Novel P2Y12 Receptor Inhibitor

Itsik Ben-Dor*, Mickey Scheinowitz, Ron Waksman

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Original languageEnglish
Title of host publicationPharmacology in the Catheterization Laboratory
Number of pages8
ISBN (Print)9781405157049
StatePublished - 30 Oct 2009


  • Antiplatelet therapy monitoring
  • Joint Utilization of Medication to Block Platelets Optimally-Thrombolysis In Myocardial Infarction (JUMBO-TIMI)
  • OPTIMUS-3 study and prasugrel standard doses with high loading doses
  • Percutaneous coronary intervention (PCI) following acute coronary syndrome (ACS)
  • Prasugrel (CS-747, LY640315)-investigational, third-generation thienopyridine
  • Prasugrel safety and tolerability in healthy volunteers
  • Prasugrel, novel p2y12 receptor inhibitor
  • Thienopyridines-class of ADP/P2Y12 receptor inhibitors
  • Thrombotic thrombocytopenic purpura (TTP)
  • VerifyNow point of care assay with light transmission aggregometry (LTA)

Cite this